Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension. (PubMed, Mult Scler Relat Disord) - Sep 13, 2026 - "Structured extension of rituximab dosing intervals after initial treatment was feasible and was not accompanied by an apparent increase in disease activity during follow-up. These findings support further evaluation of individualized EID strategies, particularly in resource-constrained settings, but do not establish equivalence or non-inferiority to continued fixed-interval dosing."
Journal • Real-world evidence • CNS Disorders • Infectious Disease • Multiple Sclerosis • CD27
|
|
L Alexander; L Chinni; L Pandit; M Vegda; N Agasti; N Pulukuri; S Alva; Y Kadri
|